JP2012067110A5 - - Google Patents

Download PDF

Info

Publication number
JP2012067110A5
JP2012067110A5 JP2011233850A JP2011233850A JP2012067110A5 JP 2012067110 A5 JP2012067110 A5 JP 2012067110A5 JP 2011233850 A JP2011233850 A JP 2011233850A JP 2011233850 A JP2011233850 A JP 2011233850A JP 2012067110 A5 JP2012067110 A5 JP 2012067110A5
Authority
JP
Japan
Prior art keywords
use according
chlorite
disorder
tcdo
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011233850A
Other languages
English (en)
Japanese (ja)
Other versions
JP5797083B2 (ja
JP2012067110A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012067110A publication Critical patent/JP2012067110A/ja
Publication of JP2012067110A5 publication Critical patent/JP2012067110A5/ja
Application granted granted Critical
Publication of JP5797083B2 publication Critical patent/JP5797083B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011233850A 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸 Expired - Lifetime JP5797083B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54157604P 2004-02-03 2004-02-03
US60/541,576 2004-02-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006552151A Division JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015118841A Division JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Publications (3)

Publication Number Publication Date
JP2012067110A JP2012067110A (ja) 2012-04-05
JP2012067110A5 true JP2012067110A5 (https=) 2013-04-04
JP5797083B2 JP5797083B2 (ja) 2015-10-21

Family

ID=34860199

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸
JP2011233850A Expired - Lifetime JP5797083B2 (ja) 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Country Status (7)

Country Link
US (5) US7105183B2 (https=)
EP (2) EP1711191B1 (https=)
JP (3) JP5072367B2 (https=)
CN (2) CN101102781B (https=)
AU (1) AU2005213300B2 (https=)
CA (2) CA2554511C (https=)
WO (1) WO2005076819A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030126B2 (en) * 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006009505A1 (en) * 2004-07-16 2006-01-26 Gyros Patent Ab Grading of immune responses
KR101931899B1 (ko) 2005-05-09 2018-12-21 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
DK1915620T3 (da) * 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
AU2013234421B2 (en) * 2005-12-22 2015-08-27 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
EP1979269A4 (en) 2005-12-22 2013-01-02 Taiji Biomedical Inc CHLORINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) * 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
US20080113391A1 (en) * 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
CA2726345C (en) * 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
AU2009291536B2 (en) * 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
CA3081708C (en) 2009-10-19 2023-10-03 Theranos Ip Company, Llc Integrated health data capture and analysis system
US20130230499A1 (en) * 2010-03-10 2013-09-05 Michal Eisenbach-Schwartz Cellular blood markers for early diagnosis of als and for als progression
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
HUE038366T2 (hu) * 2010-08-16 2018-10-29 Allergan Inc Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US20130177629A1 (en) 2011-12-22 2013-07-11 Nuvo Research Gmbh Liposomal compositions
CN107759690A (zh) * 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CN106413721A (zh) * 2014-05-16 2017-02-15 纽拉尔图斯制药公司 用于治疗巨噬细胞相关病症的方法和组合物
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ, インコーポレイテッド Als患者の処置方法
GB2637227A (en) * 2022-05-19 2025-07-16 Neuvivo Inc Biomarkers for neurogenerative disease
US20250114396A1 (en) * 2023-07-07 2025-04-10 The Regents Of The University Of California Chlorite uses for stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213389A1 (de) * 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
DE3515745A1 (de) 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US5051414A (en) * 1989-08-03 1991-09-24 Dupont Merck Pharmaceutical Company Inhibition of HIV and other retroviruses by polyoxoanions
DE4208828A1 (de) 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
DE69821506T2 (de) * 1997-10-06 2004-12-16 Oxo Chemie Ag Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2001078775A (ja) * 1999-09-14 2001-03-27 Kokuritsu Seishin Shinkei Center マクロファージ機能調節剤
JP2003515349A (ja) * 1999-11-30 2003-05-07 オクソ ヒェミー アーゲー 遺伝子発現の解析による臨床結果の評価および予測
US6685754B2 (en) 2001-03-06 2004-02-03 Alchemix Corporation Method for the production of hydrogen-containing gaseous mixtures
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Similar Documents

Publication Publication Date Title
JP2012067110A5 (https=)
JP2013525444A5 (https=)
JP2012092110A5 (https=)
JP2014515013A5 (https=)
JP2014521659A5 (https=)
JP2015525757A5 (https=)
JP2013509429A5 (https=)
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
JP2014515737A5 (https=)
JP2014507446A5 (https=)
JP2014507482A5 (https=)
AR094202A1 (es) Productos para el cuidado oral que contienen un complejo de zinc tetrabasico-acido amino-haluro, metodo
JP2011102304A5 (https=)
JP2013520405A5 (https=)
JP2012193216A5 (https=)
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
PE20141048A1 (es) Combinacion que comprende umeclidinio y un corticosteroide
JP2014530840A5 (https=)
JP2013507408A5 (https=)
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
JP2017002035A5 (https=)
JP2016530291A5 (https=)
JP2016521684A5 (https=)
JP2013533867A5 (https=)
JP2015509514A5 (https=)